Weight loss on semaglutide follows a predictable timeline in clinical trials, but individual experiences vary. Most patients start noticing changes within the first few weeks and see significant results within 3–6 months. Here's what the data shows.
The Clinical Trial Timeline
The STEP 1 trial (68 weeks of semaglutide 2.4mg) showed weight loss that was roughly linear over the treatment period, with the rate slowing as patients approached their new weight set point:
- Weeks 1–4: Average 1–2% body weight reduction. Mostly from reduced caloric intake as appetite suppression kicks in.
- Months 1–3: Average 5–8% body weight reduction. Dose escalation is ongoing during this phase.
- Months 3–6: Weight loss continues, typically 8–12% total. Most patients are at or near therapeutic doses.
- Months 6–12: Weight loss continues at a slower rate. Total losses of 12–18% are typical for patients who tolerate the medication and maintain it.
- Month 16 (end of trial): Average 14.9% body weight reduction. About one-third of patients lost 20% or more.
What to Expect in the First Month
The first 4 weeks are typically the most challenging from a side effect standpoint and the least dramatic from a results standpoint. You're on the lowest dose (0.25mg for semaglutide), which is primarily for tolerability, not maximum effect. Nausea is most common during this phase.
Most patients notice reduced hunger and appetite within the first 1–2 weeks. Actual weight changes are modest but beginning, usually 2–5 pounds in the first month at starting doses.
When Results Accelerate
Weight loss typically accelerates as the dose increases. The clinical effect is dose-dependent, higher doses produce stronger appetite suppression. Most patients reach the maintenance dose around week 16–20, and results continue to accumulate at that dose for months afterward.
Individual Variation
Clinical averages matter, but individual responses vary significantly. Some patients lose 20%+ of body weight; others lose less despite similar doses and adherence. Factors affecting individual response include baseline metabolic health, diet composition, physical activity, insulin resistance, and genetic variation in GLP-1 receptor sensitivity.
Maximizing Results
Patients who combine GLP-1 medication with dietary changes and resistance exercise consistently achieve better outcomes than those who rely on medication alone. GLP-1 medications reduce hunger significantly, but what you eat with the remaining appetite influences both the rate and quality of weight loss (preserving muscle vs. losing muscle mass).